Phenotypes associated with this allele

• Allele Symbol: Stat3^tm1.1Xyfu
• Allele Name: targeted mutation 1.1, Xin-Yuan Fu
• Allele ID: MGI:3768533
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Stat3^tm1Xyfu/Stat3^tm1.1Xyfu Tg(Ttr-cre)10-3Xyfu/?	involves: 129S1/Sv * C57BL/6	MGI:3768557
cn2	Stat3^tm1Xyfu/Stat3^tm1.1Xyfu Tg(Myh6-cre)2182Mds/0	involves: 129S1/Sv * FVB/N	MGI:4879018

Genotype
MGI:3768557

cn1

• Allelic Composition: Stat3^tm1Xyfu/Stat3^tm1.1Xyfu; Tg(Ttr-cre)10-3Xyfu/?
• Genetic Background: involves: 129S1/Sv * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:128719 )

• mortality during the first 12 hours following a 70% hepatectomy is 35.3% compared to 5.5% in Stat3^tm1Xyfu homozygotes

• however, mortality rates after 72 hours are similar

liver/biliary system

decreased hepatocyte proliferation ( J:128719 )

• following a 70% hepatectomy or carbon tetrachloride injection, hepatocyte proliferation is less than in Stat3^tm1Xyfu homozygotes

• however, liver regeneration following hepatectomy is completed

immune system

increased neutrophil cell number ( J:128719 )

• following carbon tetrachloride injection

increased monocyte cell number ( J:128719 )

• following carbon tetrachloride injection

hematopoietic system

increased neutrophil cell number ( J:128719 )

• following carbon tetrachloride injection

increased monocyte cell number ( J:128719 )

• following carbon tetrachloride injection

cellular

decreased hepatocyte proliferation ( J:128719 )

• following a 70% hepatectomy or carbon tetrachloride injection, hepatocyte proliferation is less than in Stat3^tm1Xyfu homozygotes

• however, liver regeneration following hepatectomy is completed

Genotype
MGI:4879018

cn2

• Allelic Composition: Stat3^tm1Xyfu/Stat3^tm1.1Xyfu; Tg(Myh6-cre)2182Mds/0
• Genetic Background: involves: 129S1/Sv * FVB/N

cardiovascular system

enlarged heart ( J:86400 )

• after 6 months of age

increased heart left ventricle size ( J:86400 )

• at 200 days, mice exhibit increased left ventricular chamber size compared with wild-type mice

cardiac fibrosis ( J:86400 )

• mild at 6 months

• severe at 9 months

dilated heart ( J:86400 )

• after 6 months of age

abnormal cardiovascular system physiology ( J:86400 )

• doxorubicin-treated mice exhibit a greater decrease in cardiac systolic function compared with similarly treated wild-type mice

decreased cardiac muscle contractility ( J:86400 )

• at 200 days

increased cardiomyocyte apoptosis ( J:86400 )

• LPS-treated mice exhibit increased myocyte apoptosis compared with similarly treated wild-type mice

congestive heart failure ( J:86400 )

• after 6 months of age

immune system

increased tumor necrosis factor secretion ( J:86400 )

• in the cardiac myocytes of LPS-treated mice

increased susceptibility to endotoxin shock ( J:86400 )

• LPS-treated mice exhibit increased myocyte apoptosis and TNF-alpha levels in cardiac myocytes compared with similarly treated wild-type mice

homeostasis/metabolism

ascites ( J:86400 )

• after 6 months of age

increased physiological sensitivity to xenobiotic ( J:86400 )

• doxorubicin-treated mice exhibit a greater decrease in cardiac systolic function compared with similarly treated wild-type mice

respiratory system

respiratory distress ( J:86400 )

• after 6 months of age

growth/size/body

enlarged heart ( J:86400 )

• after 6 months of age

cachexia ( J:86400 )

• after 6 months of age

muscle

decreased cardiac muscle contractility ( J:86400 )

• at 200 days

increased cardiomyocyte apoptosis ( J:86400 )

• LPS-treated mice exhibit increased myocyte apoptosis compared with similarly treated wild-type mice

cellular

increased cardiomyocyte apoptosis ( J:86400 )

• LPS-treated mice exhibit increased myocyte apoptosis compared with similarly treated wild-type mice